Economic Atlas
WORKSPACE
OverviewScreenerWatchlistChatAccount
EXPLORE
CompaniesPlacesPlace screenerMethodology
Terms·Privacy
Economic Atlas
HomeScreenerChatCompanies
Economic Atlas
WORKSPACE
OverviewScreenerWatchlistChatAccount
EXPLORE
CompaniesPlacesPlace screenerMethodology
Terms·Privacy
Economic Atlas
Companies/Galectin Therapeutics Inc.
Company profile

Galectin Therapeutics Inc.

NASDAQ: GALT · Healthcare · Biotechnology
PublicHQ Norcross, GA · GwinnettCIK 0001133416Reports USD
#1 of 1,394 Healthcare companies by revenue
EA Score
——
FH 19DQ —GM —SS 62
v0.1 · 35/100 weight · pillars only
↑ listing tenure, market scale · ↓ balance-sheet leverage, Piotroski F
Methodology →
Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$30.8M
Employees
15
Market cap
$297.0M
OverviewFinancialsSegmentsFilingsESGPeople & Places

Financials — latest annual

SEC EDGAR · USD-normalized
ConceptUSDNativeFY
Net income-$30.8M-$30.8M2025
Operating income-$20.1M-$20.1M2025
Total assets$19.5M$19.5M2025
Liabilities$145.7M$145.7M2025
Equity-$127.9M-$127.9M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Galectin Therapeutics Inc. earned -$30.8M in FY2025 net income.

Peers · Healthcare
Sight Sciences, Inc.52DCipher Pharmaceuticals Inc.84B+MacroGenics, Inc.54DOraSure Technologies, Inc.67B
Neighbors
Gwinnett →
Primerica, Inc.$3.3B77B+AGCO Corporation$10.1B63CNational Vision Holdings, Inc.$2.0B58CFox Factory Holding Corp.$1.5B46DOneWater Marine Inc.$1.9B45DGuided Therapeutics, Inc.$767.0k42D
Key facts
CEOJoel Lewis
SectorHealthcare
IndustryBiotechnology
HeadquartersNorcross, GA
ExchangeNASDAQ: GALT
Employees15
IPO date2002-09-04
Latest filings
8-K2026-06-238-K2026-05-1510-Q2026-05-158-K2026-03-3110-K2026-03-318-K2026-03-178-K2026-01-218-K2026-01-12
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.
HomeScreenerChatCompanies